12 PENNS TRAIL, NEWTOWN, PA
Changes in Board, Management or Compensation
Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Annual Report to Security Holders
Adds John Leaman, MD as Independent Director and Formalizes Appointments of Two Key Executives
News, Material Contracts
August 2025 Corporate Presentation
Reports Second Quarter 2025 Results and Business Highlights
Q2
Q1
Amended Annual Report
FY 2024
Q3
Notice of Late Filing for Quarterly Report
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership